These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
414 related articles for article (PubMed ID: 29945962)
1. Loss of Estrogen-Regulated Zhang W; Wu M; Chong QY; Zhang M; Zhang X; Hu L; Zhong Y; Qian P; Kong X; Tan S; Li G; Ding K; Lobie PE; Zhu T Cancer Res; 2018 Sep; 78(17):4915-4928. PubMed ID: 29945962 [TBL] [Abstract][Full Text] [Related]
2. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer. Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377 [No Abstract] [Full Text] [Related]
3. Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells. Zhang X; Zhang B; Zhang P; Lian L; Li L; Qiu Z; Qian K; Chen A; Liu Q; Jiang Y; Cui J; Qi B PLoS One; 2019; 14(5):e0217181. PubMed ID: 31120927 [TBL] [Abstract][Full Text] [Related]
4. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer. Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905 [TBL] [Abstract][Full Text] [Related]
5. Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression. Zhu J; Zou Z; Nie P; Kou X; Wu B; Wang S; Song Z; He J Cell Death Dis; 2016 Nov; 7(11):e2454. PubMed ID: 27809310 [TBL] [Abstract][Full Text] [Related]
6. miR-489 Confines Uncontrolled Estrogen Signaling through a Negative Feedback Mechanism and Regulates Tamoxifen Resistance in Breast Cancer. Soni M; Saatci O; Gupta G; Patel Y; Keerthi Raja MR; Li J; Liu X; Xu P; Wang H; Fan D; Sahin O; Chen H Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897675 [TBL] [Abstract][Full Text] [Related]
7. MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells. Cui J; Yang Y; Li H; Leng Y; Qian K; Huang Q; Zhang C; Lu Z; Chen J; Sun T; Wu R; Sun Y; Song H; Wei X; Jing P; Yang X; Zhang C Oncogene; 2015 Jul; 34(30):3895-907. PubMed ID: 25531331 [TBL] [Abstract][Full Text] [Related]
8. miRNA-34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells. Lee YM; Lee JY; Ho CC; Hong QS; Yu SL; Tzeng CR; Yang PC; Chen HW Breast Cancer Res; 2011; 13(6):R116. PubMed ID: 22113133 [TBL] [Abstract][Full Text] [Related]
9. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. Zhao JJ; Lin J; Yang H; Kong W; He L; Ma X; Coppola D; Cheng JQ J Biol Chem; 2008 Nov; 283(45):31079-86. PubMed ID: 18790736 [TBL] [Abstract][Full Text] [Related]
10. MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators. Ljepoja B; García-Roman J; Sommer AK; Wagner E; Roidl A Breast; 2019 Feb; 43():31-38. PubMed ID: 30415143 [TBL] [Abstract][Full Text] [Related]
11. Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells. Lin JH; Tu SH; Chen LC; Huang CC; Chang HL; Cheng TC; Chang HW; Wu CH; Wu HC; Ho YS Breast Cancer Res Treat; 2018 Nov; 172(1):45-59. PubMed ID: 30054830 [TBL] [Abstract][Full Text] [Related]
12. Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer. Thewes V; Simon R; Schroeter P; Schlotter M; Anzeneder T; Büttner R; Benes V; Sauter G; Burwinkel B; Nicholson RI; Sinn HP; Schneeweiss A; Deuschle U; Zapatka M; Heck S; Lichter P Cancer Res; 2015 Feb; 75(4):720-31. PubMed ID: 25643697 [TBL] [Abstract][Full Text] [Related]
13. miR-190 enhances endocrine therapy sensitivity by regulating SOX9 expression in breast cancer. Yu Y; Yin W; Yu ZH; Zhou YJ; Chi JR; Ge J; Cao XC J Exp Clin Cancer Res; 2019 Jan; 38(1):22. PubMed ID: 30658681 [TBL] [Abstract][Full Text] [Related]
14. ObRb downregulation increases breast cancer cell sensitivity to tamoxifen. Qian Y; Shi D; Qiu J; Zhu F; Qian J; He S; Shu Y; Yin Y; Chen X Tumour Biol; 2015 Sep; 36(9):6813-21. PubMed ID: 25846733 [TBL] [Abstract][Full Text] [Related]
15. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. Ward A; Shukla K; Balwierz A; Soons Z; König R; Sahin O; Wiemann S J Pathol; 2014 Aug; 233(4):368-79. PubMed ID: 24752803 [TBL] [Abstract][Full Text] [Related]
16. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells. Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366 [TBL] [Abstract][Full Text] [Related]
17. miR-125a-3p inhibits ERα transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor-positive breast cancer. Zheng L; Meng X; Li X; Zhang Y; Li C; Xiang C; Xing Y; Xia Y; Xi T FASEB J; 2018 Feb; 32(2):588-600. PubMed ID: 28939591 [TBL] [Abstract][Full Text] [Related]
18. Aberrant expression of SETD1A promotes survival and migration of estrogen receptor α-positive breast cancer cells. Jin ML; Kim YW; Jin HL; Kang H; Lee EK; Stallcup MR; Jeong KW Int J Cancer; 2018 Dec; 143(11):2871-2883. PubMed ID: 30191958 [TBL] [Abstract][Full Text] [Related]
19. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells. Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079 [TBL] [Abstract][Full Text] [Related]
20. miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer. Tian X; Zhang Z IUBMB Life; 2018 Jan; 70(1):71-80. PubMed ID: 29247596 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]